Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Receivables: 2020-2022

Historic Receivables for SAB Biotherapeutics (SABS) over the last 3 years, with Dec 2022 value amounting to $5.6 million.

  • SAB Biotherapeutics' Receivables fell 96.21% to $364,117 in Q2 2023 from the same period last year, while for Jun 2023 it was $19.6 million, marking a year-over-year decrease of 60.74%. This contributed to the annual value of $5.6 million for FY2022, which is 30.69% down from last year.
  • Latest data reveals that SAB Biotherapeutics reported Receivables of $5.6 million as of FY2022, which was down 30.69% from $8.0 million recorded in FY2021.
  • SAB Biotherapeutics' Receivables' 5-year high stood at $20.6 million during FY2020, with a 5-year trough of $5.6 million in FY2022.
  • For the 3-year period, SAB Biotherapeutics' Receivables averaged around $11.4 million, with its median value being $8.0 million (2021).
  • Data for SAB Biotherapeutics' Receivables shows a maximum YoY tumbled of 61.04% (in 2021) over the last 5 years.
  • Yearly analysis of 3 years shows SAB Biotherapeutics' Receivables stood at $20.6 million in 2020, then slumped by 61.04% to $8.0 million in 2021, then tumbled by 30.69% to $5.6 million in 2022.